logo
  

CMA Finds Concerns In Sika AG, MBCC Deal

The Competition and Markets Authority or CMA has found that the anticipated purchase of MBCC Group by Sika AG (SXYAY.PK,SKFOF.PK) could lead to a loss of competition in the supply of chemical admixtures in the UK. Sika announced its intention to acquire MBCC, in a deal valued around 4.5 billion pounds, in November 2021.

"The loss of competition that this deal could bring about could lead to higher prices and poorer quality products for customers, increasing the costs of these projects," said Colin Raftery, Senior Director of Mergers at the CMA.

Sika and MBCC now have 5 working days to submit proposals to address the CMA's concerns. If suitable proposals are not submitted, the deal will be referred for an in-depth phase 2 probe.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT